RxSight, Inc.
RXST
$8.43
$0.212.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.68% | 46.69% | 57.08% | 67.51% | 71.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.68% | 46.69% | 57.08% | 67.51% | 71.90% |
| Cost of Revenue | 1.74% | 12.72% | 16.06% | 22.49% | 22.03% |
| Gross Profit | 40.89% | 66.32% | 84.03% | 101.70% | 117.07% |
| SG&A Expenses | 26.71% | 30.32% | 35.46% | 35.82% | 34.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.34% | 24.48% | 27.03% | 27.95% | 26.37% |
| Operating Income | -0.39% | 22.66% | 26.41% | 27.93% | 26.54% |
| Income Before Tax | 12.45% | 40.44% | 43.60% | 44.23% | 38.14% |
| Income Tax Expenses | 294.74% | 103.45% | 150.00% | -53.49% | -38.71% |
| Earnings from Continuing Operations | 12.29% | 40.34% | 43.52% | 44.23% | 38.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.29% | 40.34% | 43.52% | 44.23% | 38.14% |
| EBIT | -0.39% | 22.66% | 26.41% | 27.93% | 26.54% |
| EBITDA | -2.65% | 22.56% | 27.66% | 30.45% | 28.89% |
| EPS Basic | 20.87% | 46.68% | 49.93% | 52.45% | 49.16% |
| Normalized Basic EPS | 17.78% | 44.55% | 48.18% | 51.02% | 50.89% |
| EPS Diluted | 20.87% | 46.68% | 49.93% | 52.45% | 49.16% |
| Normalized Diluted EPS | 17.78% | 44.55% | 48.18% | 51.02% | 50.89% |
| Average Basic Shares Outstanding | 9.85% | 11.29% | 12.84% | 16.38% | 20.64% |
| Average Diluted Shares Outstanding | 9.85% | 11.29% | 12.84% | 16.38% | 20.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |